Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Zengel, Pamela ^a   Ramp, Diana ^b   Mack, Brigitte ^a   Zahler, Stefan ^c   Berghaus, Alexander ^a   Muehlenweg, Bernd ^d   Gires, Olivier ^a,c   Schmitz, Suna ^e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Wilex Biotechnology GmbH   (Germany)

^e Amper Kliniken AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; ILOMASTAT; PLASMINOGEN ACTIVATOR INHIBITOR; PROSTAGLANDIN SYNTHASE; PROTEINASE; UNCLASSIFIED DRUG; WX UK 1; PEPTIDE HYDROLASE; UROKINASE;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER INHIBITION; CARCINOMA CELL; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; NEWBORN; TUMOR VASCULARIZATION; UMBILICAL VEIN; UTERINE CERVIX CARCINOMA; VASCULAR ENDOTHELIUM; ANIMAL; CANCER INVASION; CELL STRAIN 3T3; COCULTURE; HEAD AND NECK TUMOR; METABOLISM; METASTASIS; METHODOLOGY; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COCULTURE TECHNIQUES; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HELA CELLS; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NIH 3T3 CELLS; PEPTIDE HYDROLASES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77949469745     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-92     Document Type: Article

References (42)

1. Lang S, Wollenberg B, Dellian M, Steuer-Vogt MK, Schwenzer K, Sautier W, Chucholowski M, Eckel R, Faas I, Wilmes E, et al. [Clinical and epidemiological data of patients with malignomas of the head and neck]. Laryngorhinootologie 2002, 81(7):499-508.
2. Rovensky YA. Cellular and molecular mechanisms of tumor invasion. Biochemistry (Mosc) 1998, 63(9):1029-1043.
3. Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur J Cancer 1998, 34(8):1193-1197.
4. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295(5564):2387-2392.
5. Fong D, Steurer M, Obrist P, Barbieri V, Margreiter R, Amberger A, Laimer K, Gastl G, Tzankov A, Spizzo G. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 2006, 61(1):31-5.
6. Sturzebecher J, Vieweg H, Steinmetzer T, Schweinitz A, Stubbs MT, Renatus M, Wikstrom P. 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett 1999, 9(21):3147-3152.
7. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368(6470):419-424.
8. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997, 89(17):1260-1270.
9. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999, 43(Suppl):S42-51.
10. Hirte H, Goel R, Major P, Seymour L, Huan S, Stewart D, Yau J, Arnold A, Holohan S, Waterfield B, et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol 2000, 11(12):1579-1584.
11. Gondi CS, Rao JS. Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol 2009, 220(2):285-291.
12. Gondi CS, Rao JS. Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol 2009, 487:267-281.
13. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999, 5(12):1418-1423.
14. Nishimura G, Yanoma S, Mizuno H, Kawakami K, Tsukuda M. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999, 90(10):1152-1162.
15. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390(6658):404-407.
16. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88(2):277-285.
17. Ertongur S, Lang S, Mack B, Wosikowski K, Muehlenweg B, Gires O. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer 2004, 110(6):815-824.
18. Brenner DE. Multiagent chemopreventive agent combinations. J Cell Biochem Suppl 2000, 34:121-124.
19. Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El-Naggar AK, Lewin JS, Lippman SM, Hong WK. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999, 125(10):1083-1089.
20. Yoshida N, Granger DN, Anderson DC, Rothlein R, Lane C, Kvietys PR. Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Am J Physiol 1992, 262(6 Pt 2):H1891-1898.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65(1-2):55-63.
22. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol Histopathol 2002, 17(2):623-637.
23. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007, 96(3):417-423.
24. Wollenberg B, Ollesch A, Maag K, Funke I, Wilmes E. [Micrometastases in bone marrow of patients with cancers in the head and neck area]. Laryngorhinootologie 1994, 73(2):88-93.
25. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8(10):755-768.
26. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70.
27. Friedl P, Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res 2008, 68(18):7247-7249.
28. Wolf K, Friedl P. Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin Exp Metastasis 2009, 26(4):289-298.
29. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983, 35(3 Pt 2):611-619.
30. Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009, 9(1):32-71.
31. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998, 273(45):29864-29872.
32. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996, 2(4):461-462.
33. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1(1):27-31.
34. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998, 58(5):1048-1051.
35. Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, Varki NM, Appelt K. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin Cancer Res 1999, 5(7):1905-1917.
36. Kwak YE, Jeon NK, Kim J, Lee EJ. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Ann N Y Acad Sci 2007, 1095:99-112.
37. Boghaert ER, Chan SK, Zimmer C, Grobelny D, Galardy RE, Vanaman TC, Zimmer SG. Inhibition of collagenolytic activity relates to quantitative reduction of invasion in vitro in a c-Ha-ras transfected glial cell line. J Neurooncol 1994, 21(2):141-150.
38. Williams CS, Goldman AP, Sheng H, Morrow JD, DuBois RN. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia 1999, 1(2):170-176.
39. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18(55):7908-7916.
40. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004, 215(1):1-20.
41. Hasegawa K, Ohashi Y, Ishikawa K, Yasue A, Kato R, Achiwa Y, Nishio E, Udagawa Y. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. Int J Oncol 2005, 26(5):1419-1428.
42. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 2005, 7(4):R422-435.